EVIDENCE MAP OF INDIRECT COSTS IN PSORIASIS AND PSORIATIC ARTHRITIS SINCE 1960

Author(s)

Martin A
Crystallise Ltd., East Tilbury, UK

OBJECTIVES: To create an evidence map of studies reporting the indirect costs associated with psoriasis and psoriatic arthritis, and the geographical settings in which these studies were conducted.

METHODS: We searched the heoro.com database (www.heoro.com) for abstracts reporting indirect costs in psoriasis or psoriatic arthritis published between 1960 and 1st June 2017, interventions and study methodologies

RESULTS: We found a total of Twenty nine abstracts reported on observational cost of illness studies or those with patient-reported productivity assessments, nine included indirect costs in an economic model, seven assessed indirect costs as part of a clinical trial and 12 were reviews of the literature. Interventions studied included targeted therapies, in particular adalimumab (8 abstracts), etanercept (8), ustekinumab (5)and infliximab (3), phototherapy (6), corticosteroids (4) and cyclosporine (2), although no specific treatment was cited in 28 abstracts. Two papers were published before 2000, 16 between 2000 and 2009, and 39 between 2010 and 2017.

CONCLUSIONS: As with many diseases, there is a relative lack of published data on indirect costs of psoriasis and psoriatic arthritis, and of studies reporting indirect cost data were from four jurisdictions: the US, Germany, the UK and Italy

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PSS23

Topic

Economic Evaluation

Topic Subcategory

Work & Home Productivity - Indirect Costs

Disease

Sensory System Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×